On December 7, 2011, the Federal Food and Drug Administration (FDA) issued a FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). The U.S. Food and Drug Administration (FDA) is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate). Pradaxa is a blood thinning (anticoagulant) medication used to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AF), the most common type of heart rhythm abnormality.
Pradaxa Fatal Blood Loss Lawsuit, Defective Blood Thinner Medication Lawsuit, Pradaxa Internal Bleeding Lawsuit, Pradaxa Hemorrhaging Death Lawsuit, Pradaxa Internal Bleeding Death Lawsuit, and Pradaxa Lawsuit Information by Texas Pradaxa Fatal Blood Loss Lawyer, Pradaxa Hemorrhaging Death Lawyer, and Pradaxa Death Lawyer Jason S. Coomer
Scientific evidence has recently confirmed that the the blood thinner, Pradaxa, may cause serious health problems including internal bleeding and hemorrhaging in certain populations of patients that may cause death. Further, there are allegations that the drug manufacturer may have been aware of certain dangers of the drug's use, but did not warn the public in a timely manner of these health dangers. Several Pradaxa lawsuits have already been filed and many more are expected in the future.
The Blood Thinner Pradaxa May Cause Risk of Fatal Blood Loss, Internal Bleeding, Hemorrhaging, And Death: Persons Taking Pradaxa Should Be Aware of These Potential Health Risks by Texas Pradaxa Lawyer, Texas Pradaxa Fatal Blood Loss Lawyer, Texas Pradaxa Hemorrhaging Death Lawyer, and Texas Pradaxa Death Lawyer Jason S. Coomer